Journal of Clinical Psychopharmacology最新文献_第6页

Quetiapine in the Treatment of Comorbid Burning Mouth Syndrome and Bipolar II Depression: Case Report. 喹硫平治疗合并口腔烧灼综合征和躁狂 II 型抑郁症：病例报告。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-07-01 Epub Date: 2024-05-16 DOI: 10.1097/JCP.0000000000001868

Michael Poyurovsky, Abraham Weizman

引用次数: 0

Hypotension and Peripheral Edema With Moclobemide: A Rare Case Report. 莫氯贝胺引起的低血压和外周水肿：罕见病例报告。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-07-01 Epub Date: 2024-05-16 DOI: 10.1097/JCP.0000000000001856

Gonca Aşut

引用次数: 0

Combination Treatment With Varenicline and Nicotine Patch on Smoking Cessation Outcomes in Heavy Drinkers at 26-Week Follow-up. 伐尼克兰和尼古丁贴片联合治疗对酗酒者戒烟效果的影响（26 周随访）。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-07-01 Epub Date: 2024-05-16 DOI: 10.1097/JCP.0000000000001864

Layne E Robinson, Nathan Didier, Riya Thomas, Ashley Vena, Andrea King

{"title":"Combination Treatment With Varenicline and Nicotine Patch on Smoking Cessation Outcomes in Heavy Drinkers at 26-Week Follow-up.","authors":"Layne E Robinson, Nathan Didier, Riya Thomas, Ashley Vena, Andrea King","doi":"10.1097/JCP.0000000000001864","DOIUrl":"10.1097/JCP.0000000000001864","url":null,"abstract":"Purpose/background: People who smoke cigarettes and drink alcohol heavily are less likely to quit smoking compared with those who do not drink heavily. The current study examined the effects of a 12-week treatment phase of combination varenicline and nicotine patch compared with placebo and nicotine patch on smoking cessation (primary outcome) and alcohol consumption (secondary outcome) in heavy drinking smokers at 26-week follow-up.Methods/procedures: Participants were daily smokers who met heavy drinking criteria. They were randomly assigned to receive either varenicline and nicotine patch (n = 61) or placebo and nicotine patch (n = 61) for 12 weeks. At week 26, self-reports of point prevalence cigarette abstinence were biochemically confirmed, and past-month alcohol drinking days and heavy drinking days were assessed.Findings/results: At week 26, smoking quit rates did not differ by treatment group (25% varenicline and 26% placebo). Relative to week 12 outcomes, week 26 quit rates significantly dropped off in the varenicline group but not in the placebo group. Alcohol drinking reductions for the whole sample that were previously observed from baseline to week 12 were sustained at week 26, although they did not differ between treatment groups.Implications/conclusions: In heavy drinking smokers, smoking cessation success was evident in a quarter of the total sample at 3 months postmedication discontinuation. At this time, quit rates were the same between those who received varenicline and nicotine patch and those who received nicotine patch alone. Future research is warranted to examine what may aid in longer-term smoking quit rates in heavy drinking smokers.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"362-368"},"PeriodicalIF":2.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11211054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140945011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Floxing and Clinical Psychopharmacology. 浮肿与临床精神药理学》（Floxing and Clinical Psychopharmacology）。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-07-01 DOI: 10.1097/JCP.0000000000001890

Richard I Shader

引用次数: 0

Lithium Exposure and Risk of Major Neurocognitive Disorders: A Systematic Review and Meta-analysis. 锂暴露与主要神经认知障碍的风险：系统回顾与元分析》。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-07-01 Epub Date: 2024-05-15 DOI: 10.1097/JCP.0000000000001863

Qing Huang, Xue-Qin Ma, Hui-Fang Chen

{"title":"Lithium Exposure and Risk of Major Neurocognitive Disorders: A Systematic Review and Meta-analysis.","authors":"Qing Huang, Xue-Qin Ma, Hui-Fang Chen","doi":"10.1097/JCP.0000000000001863","DOIUrl":"10.1097/JCP.0000000000001863","url":null,"abstract":"Background: Published studies on the association between lithium use and the decreased risk of major neurocognitive disorders (MNCDs) have shown disparities in their conclusions. We aimed to provide updated evidence of this association.Methods: A comprehensive literature search was performed in PubMed, EMBASE, and Cochrane Library from inception until August 31, 2023. All the observational studies evaluating the association between lithium use and MNCD risk were eligible for inclusion. Pooled odds ratios (ORs) and 95% prediction intervals were computed using random-effects models.Results: Eight studies with 377,060 subjects were included in the analysis. In the general population on the association between lithium use versus nonuse and dementia, the OR was 0.94 (95% confidence interval [CI] = 0.77-1.24). Further analysis also demonstrated that lithium use was not associated with an increased risk of Alzheimer's disease (OR = 0.69, 95% CI: 0.31-1.65). When the analysis was restricted to individuals with bipolar disorder to reduce the confounding by clinical indication, lithium exposure was also not associated with a decreased risk of MNCD (OR = 0.9, 95% CI = 0.71-1.15).Conclusion: The results of this systematic review and meta-analysis do not support a significant association between lithium use and the risk of MNCD.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"418-423"},"PeriodicalIF":2.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140922271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

You Shall Not Turn a Blind Eye to Intraocular Pressure: A Case Report of Comorbid Panic Disorder and Angle-Closure Glaucoma. 不可对眼压视而不见：恐慌症与闭角型青光眼并发症的病例报告。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-07-01 Epub Date: 2024-06-04 DOI: 10.1097/JCP.0000000000001878

Pablo Eduardo Pereira Dutra, Laiana Azevedo Quagliato, Natia Horato, Cristiane Pereira de Souza, Bruna Dantas Dias da Silva, Antonio Egidio Nardi

引用次数: 0

Asthma and Atypical Antipsychotics: A Systematic Literature Review and Case Report of Respiratory Side Effects With Lurasidone, Cariprazine, and Lumateperone. 哮喘与非典型抗精神病药物：关于鲁拉西酮、卡里普嗪和鲁马培龙呼吸系统副作用的系统性文献综述和病例报告。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-07-01 Epub Date: 2024-06-03 DOI: 10.1097/JCP.0000000000001871

Rachel M Pacilio, Gregory W Dalack

引用次数: 0

Zuranolone Concentrations in the Breast Milk of Healthy, Lactating Individuals: Results From a Phase 1 Open-Label Study. 健康哺乳期妇女母乳中的祖诺龙浓度：一期开放标签研究结果。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-07-01 Epub Date: 2024-05-13 DOI: 10.1097/JCP.0000000000001873

Kristina M Deligiannidis, Amy Bullock, Indrani Nandy, Joi Dunbar, Robert Lasser, Michael Witte, Bridgette Leclair, Jeffrey Wald

{"title":"Zuranolone Concentrations in the Breast Milk of Healthy, Lactating Individuals: Results From a Phase 1 Open-Label Study.","authors":"Kristina M Deligiannidis, Amy Bullock, Indrani Nandy, Joi Dunbar, Robert Lasser, Michael Witte, Bridgette Leclair, Jeffrey Wald","doi":"10.1097/JCP.0000000000001873","DOIUrl":"10.1097/JCP.0000000000001873","url":null,"abstract":"Purpose/background: Zuranolone is a positive allosteric modulator of both synaptic and extrasynaptic γ-aminobutyric acid type A receptors and a neuroactive steroid approved as an oral, once-daily, 14-day treatment course for adults with postpartum depression in the United States. This study assessed zuranolone transfer into breast milk.Methods/procedures: Healthy, nonpregnant, lactating adult female participants received once-daily 30 mg zuranolone from day (D)1 through D5 in this phase 1 open-label study. The relative infant dose (RID; weight-adjusted proportion of the maternal dose in breast milk over 24 hours) for 30 mg zuranolone was assessed at D5. An RID for 50 mg zuranolone was estimated using a simulation approach across a range of infant ages and weights.Findings/results: Of 15 enrolled participants (mean age, 30.1 years), 14 completed the study. The mean RID for 30 mg zuranolone at D5 was 0.357%; the mean steady-state milk volume over D3 to D5 decreased from baseline by 8.3%. Overall unbound zuranolone in plasma was low (≤0.49%). Plasma concentrations peaked at D5 before decreasing in a biexponential manner. There was strong concordance between the temporal profiles of zuranolone concentrations in plasma and breast milk. The estimated mean RID for 50 mg zuranolone based on a milk intake of 200 mL/kg per day was 0.984%. All treatment-emergent adverse events reported by participants were mild, the most common being dizziness (n = 3).Implications/conclusions: Zuranolone transfer into the breast milk of healthy, nonpregnant, lactating adult female participants was low; the estimated RID for 50 mg zuranolone was <1%, well below the <10% threshold generally considered compatible with breastfeeding.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"337-344"},"PeriodicalIF":2.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140911887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sustained Treatment Response and Global Improvements With Long-term Valbenazine in Patients With Tardive Dyskinesia. 对迟发性运动障碍患者长期使用戊苯那嗪可获得持续治疗反应和全面改善

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-07-01 Epub Date: 2024-05-20 DOI: 10.1097/JCP.0000000000001860

Christoph U Correll, Leslie Citrome, Carlos Singer, Jean-Pierre Lindenmayer, Celia Zinger, Grace Liang, Eduardo Dunayevich, Stephen R Marder

{"title":"Sustained Treatment Response and Global Improvements With Long-term Valbenazine in Patients With Tardive Dyskinesia.","authors":"Christoph U Correll, Leslie Citrome, Carlos Singer, Jean-Pierre Lindenmayer, Celia Zinger, Grace Liang, Eduardo Dunayevich, Stephen R Marder","doi":"10.1097/JCP.0000000000001860","DOIUrl":"10.1097/JCP.0000000000001860","url":null,"abstract":"Purpose/background: Using data from KINECT® 4, a phase 3, 48-week study of valbenazine, post hoc analyses were conducted to assess long-term outcomes that are relevant to the real-world management of tardive dyskinesia (TD).Methods/procedures: Post hoc analyses of the participants of the KINECT 4 study who completed 48 weeks of open-label valbenazine (40 or 80 mg) treatment were conducted. Valbenazine effects on TD were evaluated using the Abnormal Involuntary Movement Scale (AIMS), Clinical Global Impression of Change-TD (CGI-TD), and Patient Global Impression of Change (PGIC).Findings/results: Of 103 participants completing 48 weeks of treatment, 55% experienced clinically meaningful improvement (defined as ≥2-point reduction in AIMS total score [sum of items 1 - 7, evaluated by site raters]) by week 4; at week 48, 97% met this threshold. The percentage of completers who achieved AIMS total score response thresholds of ≥10% to ≥90% increased over time, with 86% of completers reaching ≥50% improvement. Of the 40 (39%) completers with AIMS ≥50% response at week 8, 38 (95%) sustained this response at week 48; 81% of those who did not meet this threshold at week 8 had achieved it by week 48. At week 48, more than 85% of completers achieved CGI-TD and PGIC ratings of \"much improved\" or \"very much improved.\"Implications/conclusions: The majority of participants who completed 48 weeks of treatment with once-daily valbenazine experienced substantial clinically meaningful and sustained TD improvements. These findings indicate that valbenazine can be a highly effective long-term treatment in patients with TD.","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"353-361"},"PeriodicalIF":2.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141065550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sertraline-Associated Urinary Incontinence in an Adolescent With Obsessive-Compulsive Disorder: A Case Report and Literature Review. 一名患有强迫症的青少年与舍曲林相关的尿失禁：病例报告和文献综述。

IF 2.9 3区医学

Journal of Clinical Psychopharmacology Pub Date : 2024-07-01 Epub Date: 2024-05-16 DOI: 10.1097/JCP.0000000000001865

Nacharin Phiphopthatsanee, Atiporn Therdyothin

引用次数: 0